Terns Prescription drugs Inc. (NASDAQ:TERN) is one among 15 shares with the largest hedge fund momentum, after gaining 42 hedge fund holders throughout the fourth quarter of 2025. On February 9, Leerink Companions initiated protection on Terns Prescription drugs Inc. (NASDAQ:TERN) with an Outperform ranking and a value goal of $58.
Leerink Companions famous that TERN-701, Terns Prescription drugs Inc. (NASDAQ:TERN)’s next-generation allosteric inhibitor being developed for continual myeloid leukemia, addresses a market with established focused remedy adoption. The agency expects a $4.8 billion alternative for TERN-701, whereas forecasting a further $1.4 billion in second-line and past peak revenues.
The analyst agency additionally stated that TERN-701 builds upon the medical and business success of allosteric inhibition established by Novartis’s Scemblix, which is presently on a $1.6 billion run fee as of the fourth quarter of 2025. Early Section 1 knowledge from the CARDINAL trial counsel TERN-701 could have a best-in-class profile, with increased molecular response charges and a clear security profile that allows deeper and extra sturdy goal suppression, based on the analysis agency.
Terns Prescription drugs Inc. (NASDAQ:TERN) is a clinical-stage biopharmaceutical firm that develops a portfolio of small-molecule single-agent and mixture remedy candidates for the therapy of non-alcoholic steatohepatitis and different continual liver illnesses.
Whereas we acknowledge the potential of TERN as an funding, we imagine sure AI shares supply larger upside potential and carry much less draw back threat. When you’re searching for an especially undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring pattern, see our free report on the finest short-term AI inventory.
READ NEXT: 13 Sizzling Shares to Purchase with the Highest Upside Potential and 10 Greatest Excessive-Upside Supplies Shares to Purchase
Disclosure: None. Observe Insider Monkey on Google Information.
